Proposed academic endorsement of postgraduate fellowship and physician certification programs would mark a major milestone in ISSCA’s international education platform.
MIAMI, FL — [RELEASE DATE] — Regenerative Medical Technology Group, Inc. (OTC: RMTG) (“RMTG” or the “Company”) announced a collaboration between its physician education division, the International Society for Stem Cell Application (ISSCA), and the University of Buenos Aires (UBA), one of Latin America’s most established academic institutions.
Under the collaboration as described by management, ISSCA’s postgraduate Fellowship in Cell Therapy and Tissue Engineering, together with designated physician certification and training programs, are intended to receive academic endorsement from UBA, subject to the scope and terms of the institutions’ agreement.
Founded in 2009, ISSCA has developed an international platform for physician education in regenerative medicine, cellular therapies and tissue engineering, training thousands of medical professionals in more than 40 countries.
“This collaboration represents one of the most meaningful academic milestones in ISSCA’s history,” said Emiliano Herrera, Director of ISSCA. “For more than 17 years, our organization has focused on advancing physician education in regenerative medicine. Recognition by an institution with the academic tradition of the University of Buenos Aires is a powerful acknowledgment of that work.”
The initiative is intended to strengthen the academic profile of ISSCA’s postgraduate and continuing education offerings, enhance value for participating physicians and support expansion of its international education programs.
“For our physicians, this adds another dimension of academic recognition to the programs we have built over nearly two decades,” Herrera added. “We believe it can open an important new chapter in ISSCA’s global development.”
Any university endorsement will apply only to programs expressly identified in the finalized agreement and does not itself confer a UBA degree, professional license or regulatory authorization.
About the Operating Division
The International Society for Stem Cell Application (ISSCA) is the physician education division of Global Stem Cells Group, providing postgraduate training, certifications, conferences and practical programs in regenerative medicine. www.issca.com
About RMTG
Regenerative Medical Technology Group, Inc. (OTC: RMTG) operates an integrated regenerative medicine platform through Global Stem Cells Group and its specialized businesses. www.rmtg.com
Forward-Looking Statements
This press release contains forward-looking statements under applicable securities laws, including statements regarding anticipated growth, revenues, product adoption, academic collaboration, product introductions and geographic expansion. Actual results may differ materially due to regulatory developments, operational execution, market acceptance, competition and other risks. These statements are not guarantees of future performance. The Company undertakes no duty to update them except as required by law.
Investor Relations
Regenerative Medical Technology Group, Inc. | OTC: RMTG | www.rmtg.com |
